A review on vasohibin and ocular neovascularization  

作　　者：Xiao-Nan Hu Yan Ni Jie Luan Yu-Zhi Ding 

机构地区：[1]Department of Ophthalmology,Zhongda Hospital Southeast University,Nanjing 210000,Jiangsu Province,China [2]Medical School of Southeast University,Nanjing 210000,Jiangsu Province,China

出　　处：《International Journal of Ophthalmology(English edition)》2020年第6期1004-1008,共5页国际眼科杂志（英文版）

基　　金：Supported by Natural Science Fund Project in Jiangsu Province(No.BK20180380);Nanjing Health Commission(No.YKK18260)。

摘　　要：Ischemic and neovascular disease is one of the most difficult ocular diseases to deal with nowadays.Redundancy,poor visual acuity and decreased life quality are bothering patients and ophthalmologists for decades.After vascular endothelial growth factor(VEGF)was found to be a primary factor in promoting retinal angiogenesis,intravitreal injection of anti-VEGF drugs has been the firstline treatment.Whereas,some patients are refractory to this therapy and problems of economic burden,local complications and adverse effects promote researches into other possible targets.The vasohibin(VASH)family is a newly-investigated factor in modulating ocular angiogenesis.The family includes VASH1 and VASH2,which show opposite effects of inhibiting and accelerating angiogenesis respectively.Positive results have been reported in cellular and animal experiments.With further researches,it can be a promising future target of treating ocular neovascular diseases.

关 键 词：VASOHIBIN ocular neovascularization retinal neovascularization 

分 类 号：R965[医药卫生—药理学]